Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase 2 Trial in the North Central Cancer Treatment Group

BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL). METHODS: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg int...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ansell, Stephen M., Inwards, David J., Rowland, Kendrith M., Flynn, Patrick J., Morton, Roscoe F., Moore, Dennis F., Kaufmann, Scott H., Ghobrial, Irene, Kurtin, Paul J., Maurer, Matthew, Allmer, Christine, Witzig, Thomas E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627208/
https://ncbi.nlm.nih.gov/pubmed/18543327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23580
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak